Roflumilast is used for treatment to reduce the risk of Chronic Obstructive Pulmonary Disease (COPD) exacerbations in ...

Vantage Market Research is pleased to announce the publication of its latest report, Asthma and COPD Drugs Market. This ...

China NMPA accepts for review GSK’s Nucala NDA to treat patients with chronic obstructive pulmonary disease: London, UK Friday, February 21, 2025, 09:00 Hrs [IST] GSK plc announ ...

Specialty pharmacy expands access to an innovative, steroid-free treatment NEW PROVIDENCE, NJ, UNITED STATES, March 3, 2025 /EINPresswire / -- ...

The MATINEE trial included a broad range of COPD patients, including those with chronic bronchitis ... benefit to those in need of additional treatments to reduce exacerbation risks.

Ahmedabad: Senores Pharmaceuticals Limited, through its wholly-owned subsidiary Senores Pharmaceuticals, Inc., USA, has ...

Chronic Obstructive Pulmonary disease (COPD) has been around for almost 205 years and is one of the most prevalent non-infectious diseases in our country. It is the 2nd leading cause of death and ...

Recognising this progression is vital, especially in vulnerable groups such as the elderly or those with pre-existing lung conditions like asthma or COPD.” The treatment of bronchitis and ...

GSK plc has announced that the China National Medical Products Administration has accepted for review the new drug ...

Senores Pharmaceutical added 2.18% to Rs 546.15 after the company's wholly owned subsidiary, Senores Pharmaceuticals, Inc., USA has signed an agreement to acquire Roflumilast 250 mcg and 500 mcg ...

Senores Pharma acquires ANDA for roflumilast 250 mcg and 500 mcg tablets from Breckenridge Pharma: Our Bureau, Bengaluru Monday, February 24, 2025, 14:45 Hrs [IST] Senores Pharmac ...